Ewing SarcomaBEARNCT07188532
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
A study testing Biospecimen Collection, Chemotherapy and Computed Tomography in people with Ewing Sarcoma and Round Cell Sarcoma With EWSR1-non-ETS Fusion, run by Mayo Clinic at 2 sites in United States.
Trial summary
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Read more about this study
- Who is it for?
- Ages 2 years and older
- Conditions the study is for
- Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
- What is being tested?
- Biospecimen Collection, Chemotherapy and Computed Tomography
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 170 participants
- Where
- 2 sitesUnited States
- Study dates
- 5 Dec 2025to 25 Aug 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial
- Patients of age ≥ 2 years are eligible for the study
- Lansky or Karnofsky performance status ≥ 70
- Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
- Willing to provide blood samples for correlative research purposes
- Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel if tumor size is >= 8 cm
Who cannot join
- Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
- Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes
- Note: Co-enrollment on another clinical trial is allowed per the treating radiation oncologist's discretion
- Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
- Patients that have severe co-morbid systemic illness or other disease which would interfere significantly with the current treatment or measurement of outcomes
- Patients that have active uncontrolled systemic infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness or social situation that would limit study adherence
Show all 9Show fewer
- Any of the following:
- Pregnant patients
- Nursing patients
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Mayo Clinic in Arizona
Phoenix, Arizona, 85054
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Safia K. Ahmed, MD
- Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Roman O. Kowalchuk, MD
About this study
Official title: Biologically-Adapted, Dose-Escalated Accelerated Radiotherapy for Ewing Sarcoma (BEAR)
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are higher than those used in conventional radiotherapy. Larger tumor sizes and other tumor-specific characteristics have been shown to be related to poorer outcomes. In addition, after dose-escalated radiotherapy, patients with larger tumors have demonstrated improved control of the disease at the primary tumor site. Giving biologically-adapted, dose-escalated radiotherapy may reduce the return of the cancer at the primary tumor site in patients with Ewing sarcoma with large tumors and other unfavorable characteristics. This clinical trial also evaluates the role of biomarkers in patients with Ewing sarcoma. Studying samples of blood and tumor tissue from patients with Ewing sarcoma in the laboratory may help doctors learn more about predicting the amount of disease and the likelihood of the cancer coming back.
- Being tested
- Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection
- Medical subject headings
- Sarcoma, Ewing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biospecimen CollectionProcedure or surgery
Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo blood sample collection
ChemotherapyDrug
Also called Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General
Given chemotherapy
Computed TomographyProcedure or surgery
Also called CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography
Undergo CT or PET/CT
Conventional RadiotherapyProcedure or surgery
Also called 2-Dimensional Conventional Radiation Therapy, 2D Conventional Radiotherapy, 2D Radiotherapy, 2D-RT
Undergo conventional radiotherapy
Definitive Surgical ResectionProcedure or surgery
Undergo definitive surgical resection
Dose-escalated Radiation TherapyRadiation
Also called Dose-escalated RT
Undergo hypofractionated or conventional radiotherapy
Electronic Health Record ReviewOther
Ancillary studies
External Beam Radiation TherapyRadiation
Also called Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy
Undergo definitive radiotherapy
Hypofractionated Radiation TherapyRadiation
Also called Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated
Undergo hypofractionated radiation therapy
Magnetic Resonance ImagingProcedure or surgery
Also called Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan
Undergo MRI
Positron Emission TomographyProcedure or surgery
Also called Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure)
Undergo PET/CT
Questionnaire AdministrationOther
Ancillary studies
Radiation TherapyRadiation
Also called Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate
Undergo hypofractionated or conventional standard radiotherapy
| Study group | Role | What they receive |
|---|---|---|
| Cohort A Group 1 (dose-escalated radiotherapy) | Experimental | Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients then undergo hypofractionated or conventional dose-escalated radiotherapy daily, excluding weekends and holidays, for 25-36 treatment fractions in the absence of disease progression or unacceptable toxicity. Patients may also receive consolidation chemotherapy after completion of radiotherapy and/or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. Receives: Procedure: Biospecimen Collection; Drug: Chemotherapy; Procedure: Computed Tomography; Procedure: Conventional Radiotherapy; Procedure: Definitive Surgical Resection; Radiation: Dose-escalated Radiation Therapy; Other: Electronic Health Record Review; Radiation: Hypofractionated Radiation Therapy; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Other: Questionnaire Administration |
| Cohort A Group 2 (standard dose radiotherapy) | Experimental | Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients then undergo hypofractionated or conventional standard dose radiotherapy daily, excluding weekends and holidays, for 25-31 treatment fractions in the absence of disease progression or unacceptable toxicity. Patients may also receive consolidation chemotherapy after completion of radiotherapy and/or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. Receives: Procedure: Biospecimen Collection; Drug: Chemotherapy; Procedure: Computed Tomography; Procedure: Conventional Radiotherapy; Procedure: Definitive Surgical Resection; Other: Electronic Health Record Review; Radiation: Hypofractionated Radiation Therapy; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Radiation Therapy |
| Cohort B (definitive radiotherapy, surgical resection) | Experimental | Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients with tumor size < 8cm at diagnosis undergo definitive radiotherapy or surgical resection. Patients may also receive consolidation chemotherapy after completion of definitive radiotherapy or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. Receives: Procedure: Biospecimen Collection; Drug: Chemotherapy; Procedure: Computed Tomography; Procedure: Definitive Surgical Resection; Other: Electronic Health Record Review; Radiation: External Beam Radiation Therapy; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Other: Questionnaire Administration |
| Cohort C (radiotherapy, surgical resection) | Experimental | Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients undergo radiotherapy before or after undergoing definitive surgical resection. Patients may also receive consolidation chemotherapy after completion of definitive radiotherapy and surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. Receives: Procedure: Biospecimen Collection; Drug: Chemotherapy; Procedure: Computed Tomography; Procedure: Conventional Radiotherapy; Procedure: Definitive Surgical Resection; Other: Electronic Health Record Review; Radiation: External Beam Radiation Therapy; Radiation: Hypofractionated Radiation Therapy; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Radiation: Radiation Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in local failure for patients with large tumors (Cohort A)
Large tumors defined as ≥ 8cm. Will be compared to the historical control of 14.3%. Local failure will be defined per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Measured: Up to 2 years
Secondary outcomes (4)
Incidence of targeted, late grade 3 or greater adverse events (Cohort A)
Assessed per RECIST version 1.1.
Measured: Up to 1 year after completion of local therapy
Event-free survival (Cohort A)
Event-free survival (EFS) is defined as the time from study entry to any progression of disease or recurrence of disease or death from any cause, whichever occurs first.
Measured: Up to 1 year after completion of local therapy
Time to progression (Cohort A)
Will be calculated descriptively, via frequencies and percentages at various timepoints of interest, including the 1-year local control rate.
Measured: Up to 1 year after completion of local therapy
Overall survival (Cohort A)
Overall survival (OS) is defined as the time from study entry to death from any cause, estimated using the Kaplan-Meier method.
Measured: Up to 1 year after completion of local therapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2025
- Study start5 Dec 2025
- Primary completion25 Aug 2033 (estimated)
- Study completion25 Aug 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ewing SarcomaStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 170 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Roman O. Kowalchuk, MD, Principal investigator, Mayo Clinic in Rochester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07188532
- Sponsor's protocol ID
- GMROR2411
- Other IDs
- 24-004837, BEAR
- Acronym
- BEAR
- Status last verified
- Oct 2026
- First submitted
- 16 Sep 2025
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biologically-Adapted, Dose-Escalated Accelerated Radiotherapy for Ewing Sarcoma (BEAR)
- ClinicalTrials.gov ID
- NCT07188532
- Acronym / sponsor ID
- BEAR / GMROR2411
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 170 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 5 Dec 2025 (actual)
- Primary completion
- 25 Aug 2033 (estimated)
- Study completion
- 25 Aug 2033 (estimated)
- First posted
- 23 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are higher than those used in conventional radiotherapy. Larger tumor sizes and other tumor-specific characteristics have been shown to be related to poorer outcomes. In addition, after dose-escalated radiotherapy, patients with larger tumors have demonstrated improved control of the disease at the primary tumor site. Giving biologically-adapted, dose-escalated radiotherapy may reduce the return of the cancer at the primary tumor site in patients with Ewing sarcoma with large tumors and other unfavorable characteristics. This clinical trial also evaluates the role of biomarkers in patients with Ewing sarcoma. Studying samples of blood and tumor tissue from patients with Ewing sarcoma in the laboratory may help doctors learn more about predicting the amount of disease and the likelihood of the cancer coming back.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Cohort A Group 1 (dose-escalated radiotherapy) | Experimental | Procedure: Biospecimen Collection, Drug: Chemotherapy, Procedure: Computed Tomography, Procedure: Conventional Radiotherapy, Procedure: Definitive Surgical Resection, Radiation: Dose-escalated Radiation Therapy, Other: Electronic Health Record Review, Radiation: Hypofractionated Radiation Therapy, Procedure: Magnetic Resonance Imaging, Procedure: Positron Emission Tomography, Other: Questionnaire AdministrationPatients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients then undergo hypofractionated or conventional dose-escalated radiotherapy daily, excluding weekends and holidays, for 25-36 treatment fractions in the absence of disease progression or unacceptable toxicity. Patients may also receive consolidation chemotherapy after completion of radiotherapy and/or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. |
| Cohort A Group 2 (standard dose radiotherapy) | Experimental | Procedure: Biospecimen Collection, Drug: Chemotherapy, Procedure: Computed Tomography, Procedure: Conventional Radiotherapy, Procedure: Definitive Surgical Resection, Other: Electronic Health Record Review, Radiation: Hypofractionated Radiation Therapy, Procedure: Magnetic Resonance Imaging, Procedure: Positron Emission Tomography, Other: Questionnaire Administration, Radiation: Radiation TherapyPatients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients then undergo hypofractionated or conventional standard dose radiotherapy daily, excluding weekends and holidays, for 25-31 treatment fractions in the absence of disease progression or unacceptable toxicity. Patients may also receive consolidation chemotherapy after completion of radiotherapy and/or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. |
| Cohort B (definitive radiotherapy, surgical resection) | Experimental | Procedure: Biospecimen Collection, Drug: Chemotherapy, Procedure: Computed Tomography, Procedure: Definitive Surgical Resection, Other: Electronic Health Record Review, Radiation: External Beam Radiation Therapy, Procedure: Magnetic Resonance Imaging, Procedure: Positron Emission Tomography, Other: Questionnaire AdministrationPatients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients with tumor size < 8cm at diagnosis undergo definitive radiotherapy or surgical resection. Patients may also receive consolidation chemotherapy after completion of definitive radiotherapy or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. |
| Cohort C (radiotherapy, surgical resection) | Experimental | Procedure: Biospecimen Collection, Drug: Chemotherapy, Procedure: Computed Tomography, Procedure: Conventional Radiotherapy, Procedure: Definitive Surgical Resection, Other: Electronic Health Record Review, Radiation: External Beam Radiation Therapy, Radiation: Hypofractionated Radiation Therapy, Procedure: Magnetic Resonance Imaging, Procedure: Positron Emission Tomography, Other: Questionnaire Administration, Radiation: Radiation TherapyPatients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients undergo radiotherapy before or after undergoing definitive surgical resection. Patients may also receive consolidation chemotherapy after completion of definitive radiotherapy and surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion. |
Who may qualify
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with "Ewing-like" sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial
- Patients of age ≥ 2 years are eligible for the study
- Lansky or Karnofsky performance status ≥ 70
- Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance
- Willing to provide blood samples for correlative research purposes
Key exclusion criteria (9 listed)
- Prior chemotherapy or radiotherapy that, in the opinion of the treating medical oncologist or radiation oncologist, is considered to interfere with the current treatment or measurement of outcomes
- Receiving any investigational agent which would be considered as a treatment for the primary neoplasm that is considered by the investigator to interfere with the current treatment or measurement of outcomes
- Other active malignancy ≤ 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes
- Patients that have severe co-morbid systemic illness or other disease which would interfere significantly with the current treatment or measurement of outcomes
- Patients that have active uncontrolled systemic infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness or social situation that would limit study adherence
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biospecimen CollectionAlso: Biological Sample Collection, Biospecimen Collected, Specimen CollectionUndergo blood sample collection | Procedure or surgery | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| ChemotherapyAlso: Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, GeneralGiven chemotherapy | Drug | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| Computed TomographyAlso: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial TomographyUndergo CT or PET/CT | Procedure or surgery | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| Conventional RadiotherapyAlso: 2-Dimensional Conventional Radiation Therapy, 2D Conventional Radiotherapy, 2D Radiotherapy, 2D-RTUndergo conventional radiotherapy | Procedure or surgery | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort C (radiotherapy, surgical resection) |
| Definitive Surgical ResectionUndergo definitive surgical resection | Procedure or surgery | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| Dose-escalated Radiation TherapyAlso: Dose-escalated RTUndergo hypofractionated or conventional radiotherapy | Radiation | Cohort A Group 1 (dose-escalated radiotherapy) |
| Electronic Health Record ReviewAncillary studies | Other | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| External Beam Radiation TherapyAlso: Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam RadiotherapyUndergo definitive radiotherapy | Radiation | Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| Hypofractionated Radiation TherapyAlso: Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, HypofractionatedUndergo hypofractionated radiation therapy | Radiation | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort C (radiotherapy, surgical resection) |
| Magnetic Resonance ImagingAlso: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging ScanUndergo MRI | Procedure or surgery | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| Positron Emission TomographyAlso: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure)Undergo PET/CT | Procedure or surgery | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| Questionnaire AdministrationAncillary studies | Other | Cohort A Group 1 (dose-escalated radiotherapy), Cohort A Group 2 (standard dose radiotherapy), Cohort B (definitive radiotherapy, surgical resection), Cohort C (radiotherapy, surgical resection) |
| Radiation TherapyAlso: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, IrradiateUndergo hypofractionated or conventional standard radiotherapy | Radiation | Cohort A Group 2 (standard dose radiotherapy), Cohort C (radiotherapy, surgical resection) |
Primary outcome
Reduction in local failure for patients with large tumors (Cohort A)
Time frame: Up to 2 years
Large tumors defined as ≥ 8cm. Will be compared to the historical control of 14.3%. Local failure will be defined per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
4 secondary outcomes
Incidence of targeted, late grade 3 or greater adverse events (Cohort A)
Time frame: Up to 1 year after completion of local therapy
Event-free survival (Cohort A)
Time frame: Up to 1 year after completion of local therapy
Time to progression (Cohort A)
Time frame: Up to 1 year after completion of local therapy
Overall survival (Cohort A)
Time frame: Up to 1 year after completion of local therapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
Related trials for Ewing Sarcoma
RecruitingPhase 1/2
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
Not yet recruitingPhase 1
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Neuroblastoma (NBL), Ewing Sarcoma
Not yet recruitingPhase 1/2
Combination Immunotherapy Targeting Sarcomas
Sarcoma, Osteoid Sarcoma
RecruitingPhase 1
International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma
High-risk GD2 Positive Ewing Sarkoma
Not yet recruitingPhase 1/2
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Sarcoma, Osteoid Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Roman O. Kowalchuk, MD principal investigator
Mayo Clinic in Rochester
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Biospecimen Collection, Chemotherapy and Computed Tomography in people with Ewing Sarcoma and Round Cell Sarcoma With EWSR1-non-ETS Fusion, run by Mayo Clinic at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Trials Referral Office (855-776-0015, mayocliniccancerstudies@mayo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in local failure for patients with large tumors (Cohort A) (time frame: Up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.